![](https://dc.citybuzz.co/media/images/medium/1597095385_NVAX.jpg)
Novavax (NASDAQ:NVAX) Q2 results:
Revenue: $35.5M (+999%) from CEPI agreement.
Net loss: ($17.5M); loss/share: ($0.30).
Cash and equivalents at quarter-end: $424.4M (+438.6%).
Secured $2B in funding to support development and commercialization of COVID-19 vaccine candidate NVX-CoV2373.
READ FULL ARTICLE HERE